M. Seguí-Palmer

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

E Mardis, E. Mardis, C. Fan, 2014, British Journal of Cancer.

Cost-effectiveness analysis of docetaxel (Taxotere®) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer

Á. Rodríguez-Lescure, M. Ruíz-Borrego, M. Seguí-Palmer, 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).

H. Wildiers, J. Jassem, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours

G. Restovic, J. Pérez-Gracia, I. Durán, 2013, Clinical and Translational Oncology.

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial.

G. Curigliano, J. Pérez-García, A. Prat, 2021, European journal of cancer.

Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab

Y. Fujiwara, M. Colleoni, V. Hanes, 2019, Targeted Oncology.

Exercise and cancer: a position statement from the Spanish Society of Medical Oncology

M. Pollán, Miguel Martín, M. Seguí-Palmer, 2020, Clinical and Translational Oncology.

Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.

E. Dalmau, M. Muñoz, M. Seguí-Palmer, 2014, Breast.

High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer.

F. Rojo, J. Albanell, A. Ruíz, 2016, The oncologist.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.